髓鞘少突胶质细胞糖蛋白抗体相关脊髓炎的临床、影像与预后特征
该回顾性研究纳入54例MOG-IgG阳性脊髓炎患者,并与AQP4-IgG及MS脊髓炎比较。MOG-IgG脊髓炎多见于年轻患者,常以孤立性横贯性脊髓炎起病,部分初诊为病毒性急性弛缓性脊髓炎。MRI示T2异常局限于灰质(矢状线征和轴位H征)且无强化,长节段病变与AQP4-IgG相似但MS未见;多数患者最终出现复发,预后优于AQP4-IgG。
要点
- MOG-IgG脊髓炎常见于年轻患者,可表现为急性弛缓性脊髓炎。
- MRI示T2异常局限于灰质(矢状线征和轴位H征)且无强化提示MOG-IgG。
- 长节段T2病变在MOG-IgG与AQP4-IgG中频率相似,但MS中未见。
核心结论
- MOG-IgG脊髓炎是MOG-IgG相关疾病的早期表现,可呈急性弛缓性脊髓炎表型。
- 多种临床和MRI特征有助于识别需检测MOG-IgG的高危患者。
研究设计与样本
- 回顾性研究,从Mayo Clinic神经免疫实验室识别199例MOG-IgG阳性患者(2000年1月1日至2017年12月31日)。
- 54例符合临床脊髓炎、MOG-IgG阳性且有病历记录;排除145例无脊髓炎记录者。
- 对照包括AQP4-IgG脊髓炎46例和MS脊髓炎26例。
主要发现
- 54例MOG-IgG脊髓炎患者中位年龄25岁(范围3-73岁),女性24例(44%)。
- 29例(54%)以孤立性横贯性脊髓炎为首发表现,10例(19%)初诊为病毒性/病毒感染后急性弛缓性脊髓炎。
- 脑脊液寡克隆带升高见于1/38(3%)。
- 中位随访24个月(范围2-120个月),32例(59%)出现至少1次复发:视神经炎31例、横贯性脊髓炎7例、急性播散性脑脊髓炎1例。
关键数值与推荐
- 支持MOG-IgG而非AQP4-IgG或MS脊髓炎的临床特征包括前驱症状和合并急性播散性脑脊髓炎。
- 支持MOG-IgG而非AQP4-IgG或MS脊髓炎的MRI特征为T2信号异常局限于灰质(矢状线征和轴位H征)且无强化。
- 多发病灶和圆锥受累在MOG-IgG中较AQP4-IgG更常见,但与MS无差异。
临床怎么用
- 对年轻脊髓炎患者,尤其表现为急性弛缓性脊髓炎或合并前驱症状、ADEM时,应检测MOG-IgG。
- MRI显示灰质局限T2异常(矢状线征、轴位H征)且无强化时,提示MOG-IgG脊髓炎可能。
- MOG-IgG脊髓炎患者需长期随访监测复发,尽管其恢复优于AQP4-IgG。
局限性
- 回顾性研究设计。
- 样本来自单中心神经免疫实验室,可能存在选择偏倚。
- 对照组样本量较小(AQP4-IgG 46例,MS 26例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recognizing the characteristics of myelin oligodendrocyte glycoprotein autoantibody (MOG-IgG) myelitis is essential for early accurate diagnosis and treatment. OBJECTIVE: To evaluate the clinical, radiologic, and prognostic features of MOG-IgG myelitis and compare with myelitis with aquaporin-4-IgG (AQP4-IgG) and multiple sclerosis (MS). DESIGN, SETTING, AND PARTICIPANTS: We retrospectively identified 199 MOG-IgG-positive Mayo Clinic patients from January 1, 2000, through December 31, 2017, through our neuroimmunology laboratory. Fifty-four patients met inclusion criteria of (1) clinical myelitis; (2) MOG-IgG positivity; and (3) medical records available. We excluded 145 patients without documented myelitis. Myelitis of AQP4-IgG (n = 46) and MS (n = 26) were used for comparison. MAIN OUTCOMES AND MEASURES: Outcome variables included modified Rankin score and need for gait aid. A neuroradiologist analyzed spine magnetic resonance imaging of patients with MOG-IgG and control patients blinded to diagnosis. RESULTS: Of 54 included patients with MOG-IgG myelitis, the median age was 25 years (range, 3-73 years) and 24 were women (44%). Isolated transverse myelitis was the initial manifestation in 29 patients (54%), and 10 (19%) were initially diagnosed as having viral/postviral acute flaccid myelitis. Cerebrospinal fluid-elevated oligoclonal bands occurred in 1 of 38 (3%). At final follow-up (median, 24 months; range, 2-120 months), 32 patients (59%) had developed 1 or more relapses of optic neuritis (n = 31); transverse myelitis (n = 7); or acute disseminated encephalomyelitis (n = 1). Clinical features favoring MOG-IgG myelitis vs AQP4-IgG or MS myelitis included prodromal symptoms and concurrent acute disseminated encephalomyelitis. Magnetic resonance imaging features favoring MOG-IgG over AQP4-IgG or MS myelitis were T2-signal abnormality confined to gray matter (sagittal line and axial H sign) and lack of enhancement. Longitudinally extensive T2 lesions were of similar frequency in MOG-IgG and AQP4-IgG myelitis (37 of 47 [79%] vs 28 of 34 [82%]; P = .52) but not found in MS. Multiple spinal cord lesions and conus involvement were more frequent with MOG-IgG than AQP4-IgG but not different from MS. Wheelchair dependence at myelitis nadir occurred in one-third of patients with MOG-IgG and AQP4-IgG but never with MS, although patients with MOG-IgG myelitis recovered better than those with AQP4-IgG. CONCLUSIONS AND RELEVANCE: Myelitis is an early manifestation of MOG-IgG-related disease and may have a clinical phenotype of acute flaccid myelitis. We identified a variety of clinical and magnetic resonance imaging features that may help clinicians identify those at risk in whom MOG-IgG should be tested.
引用
- Dubey D, Pittock SJ, Krecke KN, et al. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2019. PMID: 30575890. doi:10.1001/jamaneurol.2018.4053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。